The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months

Matthew A. Lunning, Jocelyn C. Migliacci, Patrick Hilden, Sean M. Devlin, Hugo Castro-Malaspina, Sergio Giralt, Miguel Angel Perales, Andrew D. Zelenetz, Craig H. Moskowitz, Craig S. Sauter

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Early relapsed or refractory follicular lymphoma (FL) warrants consolidation with transplantation, though graft source modality remains controversial. We analysed the outcomes of 44 patients transplanted with either autologous or allogeneic graft sources in the post-rituximab era. No difference in event-free (EFS) or overall survival (OS) was observed between allogeneic (81% and 81%) and autologous transplantation (64% and 70%) at 3 years. There was a significant difference in EFS between allogeneic and autologous transplantation patients with previous remission duration of ≤12 months (80% and 42% at 3 years, P < 0·015). Very early relapsed FL may warrant consideration of allogeneic over autologous transplantation in the appropriate setting.

Original languageEnglish (US)
Pages (from-to)260-264
Number of pages5
JournalBritish Journal of Haematology
Volume173
Issue number2
DOIs
StatePublished - Apr 1 2016

Keywords

  • Follicular lymphoma
  • Non-Hodgkin lymphoma
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months'. Together they form a unique fingerprint.

  • Cite this